NCT02969317View on ClinicalTrials.gov

Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium

Fixed dose combination

DRUG

Olodaterol

Fixed dose combination

Trial Locations (1)

610041

West China Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02969317 - Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients | Biotech Hunter | Biotech Hunter